OBJECTIVE: To compare the clinical and mycological efficacy and patient acceptability of the oral antifungal itraconazole with vaginal clotrimazole in the treatment of vaginal candidosis. DESIGN: A multicentre, single-blind, randomised, parallel group comparison of itraconazole and clotrimazole. SETTING: 17 Genito Urinary Medicine clinics in UK hospitals. SUBJECTS:Women with symptomatic, culture positive vaginal candidosis. METHODS: Patients were randomly allocated 2 x 100 mg itraconazole capsules to be taken twice in a 24 hour period, or a 500 mg clotrimazole vaginal tablet. Clinical and mycological assessments were made at entry and after approximately seven and 35 days. OUTCOME MEASURES: Cure rate was defined in terms of mycological results, and patients were questioned on their opinion of treatment. RESULTS: Of 214 patients, 109 receiveditraconazole and 105 clotrimazole with similar improvement in clinical signs and symptoms. Mycological cure rates one week after treatment were obtained in 72 of 97 patients (74%) in the itraconazole group and 64 of 89 patients (72%) in the clotrimazole group. Identical mycological cure rates six weeks after treatment were obtained with 40 of 79 patients (51%) receiving itraconazole and 39 of 78 patients (50%) receiving clotrimazole. CONCLUSION:Clotrimazole and itraconazole were found to be equally effective. A majority of patients receiving the latter preferred it to previous treatments.
RCT Entities:
OBJECTIVE: To compare the clinical and mycological efficacy and patient acceptability of the oral antifungal itraconazole with vaginal clotrimazole in the treatment of vaginal candidosis. DESIGN: A multicentre, single-blind, randomised, parallel group comparison of itraconazole and clotrimazole. SETTING: 17 Genito Urinary Medicine clinics in UK hospitals. SUBJECTS:Women with symptomatic, culture positive vaginal candidosis. METHODS:Patients were randomly allocated 2 x 100 mg itraconazole capsules to be taken twice in a 24 hour period, or a 500 mg clotrimazole vaginal tablet. Clinical and mycological assessments were made at entry and after approximately seven and 35 days. OUTCOME MEASURES: Cure rate was defined in terms of mycological results, and patients were questioned on their opinion of treatment. RESULTS: Of 214 patients, 109 received itraconazole and 105 clotrimazole with similar improvement in clinical signs and symptoms. Mycological cure rates one week after treatment were obtained in 72 of 97 patients (74%) in the itraconazole group and 64 of 89 patients (72%) in the clotrimazole group. Identical mycological cure rates six weeks after treatment were obtained with 40 of 79 patients (51%) receiving itraconazole and 39 of 78 patients (50%) receiving clotrimazole. CONCLUSION:Clotrimazole and itraconazole were found to be equally effective. A majority of patients receiving the latter preferred it to previous treatments.
Authors: Isabel Del-Cura González; Francisca García-de-Blas González; Teresa Sanz Cuesta; Jesús Martín Fernández; Justo M Del-Alamo Rodríguez; Rosa A Escriva Ferrairo; M Del Canto De-Hoyos Alonso; Laura Balsalobre Arenas; Ricardo Rodríguez Barrientos; Elisa Ceresuela Wiesmann; Cristina De-Alba Romero; Yolanda Ginés Díaz; Ana Pastor Rodríguez-Moñino; Blanca Gutiérrez Teira; Marta Sánchez-Celaya Del Pozo; Jesús Fernández Horcajuelo; María J Rojas Giraldo; Paulino Cubero González; Rocío A Vello Cuadrado; Beatriz López Uriarte; Jeannet Sánchez Yepes; Yolanda Hernando Sanz; M José Iglesias Piñeiro; Susana Tudanca Hernández; Fernando Gallardo Alonso; Ana I González González; Alicia Simón Fernández; Carmen Carballo; Ana Rey López; Fernanda Morales; Dolores Martínez López Journal: BMC Public Health Date: 2011-01-31 Impact factor: 3.295
Authors: Hayley J Denison; Julia Worswick; Christine M Bond; Jeremy M Grimshaw; Alain Mayhew; Shakila Gnani Ramadoss; Clare Robertson; Mary Ellen Schaafsma; Margaret C Watson Journal: Cochrane Database Syst Rev Date: 2020-08-24